Wainua failure sharpens—but does not settle—the TTR silencer versus stabilizer debate

AstraZeneca and Ionis’ Wainua (eplontersen) missed the primary endpoint in the 1,432-patient, 140-week CARDIO-TTRansform Phase 3 trial in ATTR-CM. Adding Wainua to standard care did not significantly reduce cardiovascular death plus recurrent cardiovascular events.

The result appears driven largely by background stabilizer use:
57% of patients in both arms were already taking a TTR stabilizer at baseline, and another 24% began one during the trial. In the baseline-stabilizer subgroup, Wainua showed no treatment effect.

By contrast, the prespecified subgroup receiving Wainua without a stabilizer showed fewer primary-endpoint events, with a nominally significant hazard ratio of about 0.71. However, this subgroup result was not sufficient to rescue the overall trial, and the study was not necessarily powered to establish monotherapy superiority.

Later detailed reporting put the overall hazard ratio at about 1.14—roughly a 14% higher rate of cardiovascular mortality or recurrent events with Wainua, though interpretation is complicated by treatment crossover and subgroup composition.

The findings strengthen the near-term case for stabilizers such as Vyndamax and Attruby in patients already receiving them, and weaken the argument that routinely combining a silencer with a stabilizer provides incremental hard-outcome benefit.

The result does not prove stabilizers are intrinsically superior to silencers. It tested eplontersen largely as add-on therapy in a contemporary, heavily treated population; it does not invalidate silencer efficacy as initial or standalone treatment, nor does it directly compare the two mechanisms head-to-head.

The commercial and clinical implication is a higher bar for next-generation TTR silencers:
developers will likely need to show clear benefit in stabilizer-treated patients, not merely potent TTR lowering or favorable results in untreated subgroups. The failure also raises questions for combination-treatment guidelines and payer willingness to reimburse dual therapy.